Abstract
Two applications claim N,N´-bisaryl urea derivatives as allosteric inhibitors of p38 MAPK and their use as anti-inflammatory agents. The compounds have been designed to stabilise a specific conformation of the kinase and to optimise selectivity by avoiding interactions with the ATP-binding domain of the kinase. They are the first application to describe the applicant’s p38 inhibitor programme, which is close to investigational new drug filing.
Keywords::
Patent details
Title Urea inhibitors of MAP kinases
Assignee Locus Pharmaceuticals Inc.
Inventors Michelotti EL, Springman EB, Nguyen D et al.
Priority date 07/12/04
Filing date 07/12/05
Publication date 15/06/06
Publication no. WO2006062982
Title Inhibitors of protein kinases
Assignee Locus Pharmaceuticals Inc
Inventors Moore WR Jr, Springman E, Michelotti E.
Priority date 07/12/04
Filing date 07/12/05
Publication date 15/06/06
Publication no. WO2006062984